US 11904017
Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11904017 (Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K31/397